Molecule 77 LLC
About Molecule 77

This page contains an overview of our company and staff biographies.

Company Status


We have created a disruptive, plant-based medicine that will change the world, offering
  • Accelerated healing of fractures
  • Increased bone density
  • Reduced inflammation
  • Reduced pain
  • Restored lost productivity due to incapacitation
  • Promotion of mental health following trauma, PTSD, anxiety and post-traumatic depression

In 2019, there were 178 million new fractures, 455 million (428—484) prevalent cases of acute or long-term symptoms of a fracture (an increase of 70·1% (67·5%—72·5%) since 1990. (Lancet Healthy Longevity, 2021 Sep;2(9):e580-e592. doi: 10.1016/S2666-7568(21)00172-0), cited Estimated potential market size: $200 billion annually worldwide.

Mission Statement

We seek to break down walls of traditional development and implementation of medicine, to quantify through science data and track and traceability, and to show medical peers globally the benefits of using M77 when treating fractures, dislocations, crushings and sprains at a cost under 20 to the patient

Business Opportunity

We seek a partner who understands, share our vision and wants to participate.

Our first round: We offer $1,000,000 in stock with a 15% ownership in Molecule 77 LLC. Our first partner will have first right to purchase any additional shares when offered through any subsidiary company’s (i.e., M77 Italy LLC).

M77 has a unique formulation. We are not in R&D phase. We have completed 100 large-animal tests with positive results: 30 to 50 percent healing. We have tested on 13 humans with great results. M77 can produce in volume.

Application of Funds

  • Acquire equipment to filter and sterilize M77 vials for first trials
  • Additional funding for clinical studies and patent

Our Team

Executive Team

John P. Wick
Managing Director
Anthony Rushford
Chief Scientist